In a recent decision, the Federal Circuit upheld the Patent Trial and Appeal Board’s (PTAB) ruling that the amended claims of a Cardiovalve Ltd. heart valve implant remain valid. This decision marks a significant moment in patent law as Edwards Lifesciences Corp. sought to challenge the PTAB’s conclusion, but the appellate court confirmed the initial findings. The Federal Circuit’s affirmation on Monday echoes the board’s stance that the amendments to the claims do not invalidate the device.
For more comprehensive details on the court’s ruling, the full text of the decision can be accessed on Law360.